

Supplementary Table S2:Reasons for literature exclusion in full-text screening

Exclusion reason	Reference number
1.Not systematic review or meta analysis.	[1]
2.Meta analysis of multiple tumors.	[2]
3.Adjuvant therapy is radiotherapy or local treatment.	[3-6]
4.No comparison between chemotherapy regimens.	[7-18]
5.Data overlapped.	[19-23]
6.OR/ HR / RR values were not calculated.	[24-27]

Reference List

- [1] Kamarajah S, Giovinazzo F, Roberts KJ, et al. The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: Review of literature and pooled analysis. *Ann Hepatobiliary Pancreat Surg*. 2020. 24(1): 6-16.
- [2] Qi WX, Tang LN, He AN, Yao Y, Shen Z. Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials. *Respir Med*. 2013. 107(8): 1280-3.
- [3] Hakeem AR, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer - A systematic review. *Eur J Surg Oncol*. 2019. 45(2): 83-91.
- [4] Chen X, Meng F, Xiong H, Zou Y. Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis. *Front Oncol*. 2021. 11: 600027.
- [5] Ray CE Jr, Edwards A, Smith MT, et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. *J Vasc Interv Radiol*. 2013. 24(8): 1218-26.
- [6] Holster JJ, El Hassnaoui M, Franssen S, et al. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. *Ann Surg Oncol*. 2022 .
- [7] Luvira V, Satitkarnmanee E, Pugkhem A, Kietpeerakool C, Lumbiganon P, Pattanittum P. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma. *Cochrane Database Syst Rev*. 2021. 9: CD012814.
- [8] Moriwaki T, Yamamoto Y, Gosho M, et al. Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy. *Br J Cancer*. 2016. 114(8): 881-8.
- [9] Messina C, Merz V, Frisinghelli M, et al. Adjuvant chemotherapy in resected bile duct cancer: A systematic review and meta-analysis of randomized trials. *Crit Rev Oncol Hematol*. 2019. 143: 124-129.
- [10] Ghidini M, Tomasello G, Botticelli A, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. *HPB (Oxford)*. 2017. 19(9): 741-748.
- [11] Grendar J, Grendarova P, Sinha R, Dixon E. Neoadjuvant therapy for

downstaging of locally advanced hilar cholangiocarcinoma: a systematic review. *HPB (Oxford)*. 2014. 16(4): 297-303.

- [12] Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. *Ann Oncol*. 2014. 25(12): 2328-2338.
- [13] Rangarajan K, Simmons G, Manas D, Malik H, Hamady ZZ. Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: A systematic review and meta-analysis. *Eur J Surg Oncol*. 2020. 46(4 Pt A): 684-693.
- [14] Caparica R, Bruzzzone M, Hachem GE, et al. Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. *Crit Rev Oncol Hematol*. 2020. 149: 102940.
- [15] Azizi AA, Lamarca A, McNamara MG, Valle JW. Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2021. 163: 103328.
- [16] Ma KW, Cheung TT, Leung B, et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis. *Medicine (Baltimore)*. 2019. 98(5): e14013.
- [17] Belkouz A, Nooijen LE, Riady H, et al. Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review. *Cancer Treat Rev*. 2020. 91: 102110.
- [18] Song S, Yang W, Tian H, et al. The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. *Clin Res Hepatol Gastroenterol*. 2022. 46(2): 101788.
- [19] Sun XF, He ZK, Sun JP, Ge QX, Shen ED. The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis. *Oncotarget*. 2017. 8(59): 100657-100667.
- [20] Yang R, Wang B, Chen YJ, Li HB, Hu JB, Zou SQ. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis. *Anticancer Drugs*. 2013. 24(8): 871-7.
- [21] Cai W, Yuan Y, Ge W, et al. EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs. *J Cancer*. 2018. 9(8): 1476-1485.
- [22] Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. *Ann Oncol*. 2014. 25(2): 391-8.
- [23] Kish M, Chan K, Perry K, Ko YJ. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers. *Curr Oncol*. 2020. 27(1): e20-e26.
- [24] Naveed S, Qari H, Thau CM, Burasakarn P, Mir AW. Neoadjuvant Chemotherapy for Advanced Gallbladder Cancer: Do We have Enough Evidence? A Systematic Review. *Euroasian J Hepatogastroenterol*. 2021. 11(2): 87-94.
- [25] Fiteni F, Nguyen T, Vernerey D, et al. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a

systematic review. *Cancer Med.* 2014. 3(6): 1502-11.

- [26] Jiang Q, Huang J, Zhang B, et al. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. *Front Immunol.* 2022. 13: 801909.
- [27] Park JO, Oh DY, Hsu C, et al. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. *Cancer Res Treat.* 2015. 47(3): 343-61.